James Schoeneck served as President, CEO and a director of Depomed, a publicly traded specialty pharmaceutical company, from 2011 until 2017. Prior to joining Depomed, Mr. Schoeneck was CEO of BrainCells Inc., ActivX BioSciences and Prometheus Laboratories Inc. Prior to Prometheus, Mr. Schoeneck led the development of Centocor’s commercial capabilities, including the market launch of Remicade®, which has become one of the most successful therapeutic antibodies in history. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck also serves on the board of FibroGen. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.